Key result
The COBRA-PzF stent, featuring a nanothin layer of Polyzene-F without added drug, demonstrates antithrombotic properties and may be especially useful in patients at high risk for bleeding.
The COBRA-PzF stent is a novel drug-free, Polyzene-F coated stent that demonstrates thromboresistance and may be particularly beneficial for patients at high bleeding risk who require shortened dual antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Should not yet change DAPT practice in high-bleeding-risk patients; hypothesis-generating for drug-free stents pending randomized trials.
The COBRA-PzF™ (CeloNova BioSciences, Inc., TX, USA) is a new type of coronary stent composed of a cobalt chromium metallic backbone surrounded by a nanothin layer of Polyzene-F (PzF) without any added drug. Evidence from basic studies supports antithrombotic and anti-inflammatory properties for the PzF surface coating. Preclinical studies support the thromboresistance of PzF-coated surfaces and clinical studies have shown good outcomes for patients receiving this device with very low rates of stent thrombosis. COBRA-PzF may be especially useful in patients at high risk for bleeding. Ongoing clinical trials will determine whether shortening the duration of dual antiplatelet therapy to less than 1 month is feasible and these data may represent a new paradigm with regards to patients at high risk for bleeding.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2018) conducted a review in Coronary artery disease (high risk for bleeding). COBRA-PzF stent was evaluated. The COBRA-PzF stent, featuring a nanothin layer of Polyzene-F without added drug, demonstrates antithrombotic properties and may be especially useful in patients at high risk for bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: